SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is actively discussed after its obesity drug's trial results did not match a key rival, leading to a significant stock dip; however, this is tempered by regulatory actions against unauthorized compounded GLP-1s and robust demand for its oral weight-loss treatment, causing a split in community sentiment between caution and buying the dip.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is generating significant buzz following impressive Phase 2 S-OLARIS trial results for sonelokimab in axial spondyloarthritis, coupled with strong financial reporting. This has led the community to discuss "disease modifying" potential and widespread anticipation of a substantial market re-rating and short covering ahead of its investor day.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending following the FDA approval of Bysanti (milsaperidone) with New Chemical Entity status and patent protection until 2044, igniting community speculation about a significant short squeeze and potential buyout offers from larger pharmaceutical firms. Investors are weighing the drug's long-term revenue potential against ongoing concerns of market manipulation and potential dilution.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is gaining attention following news that Novo Nordisk's experimental obesity drug performed below Eli Lilly's in a Phase 3 trial, intensifying community discussions and expectations for Viking's own potentially best-in-class GLP-1/GIP assets to become a prime acquisition or partnership target in the rapidly evolving market.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending high following robust earnings and an optimistic 2026 outlook, reinforcing its leadership in the GLP-1 market, especially as a key competitor provided a weaker forecast. The community is also keenly watching its pipeline diversification through recent acquisitions and the anticipated launch of its oral weight-loss therapy.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending amid fresh positive news including its Huntington's disease trial approval and strong international Elevidys sales, sparking community debate over the significant undervaluation of its commercial gene therapy franchise and deep RNA pipeline ahead of upcoming earnings, especially with notable short interest.

Polygon

Polygon is trending due to its strategic pivot towards becoming a foundational layer for payments and Real-World Assets, underpinned by recent acquisitions and record network usage driving increased token burns. Despite community frustration that its price hasn't fully reflected these developments, many are actively accumulating Polygon, citing its strong fundamentals and perceived undervaluation.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

The SPY is seeing intense discussion driven by renewed global tariff concerns after a recent ruling and subsequent policy changes, prompting a fierce debate among community members predicting either a sharp market correction or a swift V-shaped recovery amid broader geopolitical tensions and a notable crypto market downturn.

Unusual Machines, Inc. is a development stage technology company, which engages in the provision of drone solutions with a focus on first-person view (FPV) technology. It offers products to entertainment, recreation, and competitive racing industries. The company was founded on July 11, 2019, and is headquartered in Orlando, FL.

Unusual Machines Inc

Unusual Machines, Inc.

Unusual Machines (UMAC) is gaining significant attention after being named a top analyst pick and securing a new $2.1 million defense order, reinforcing its crucial role as a domestic drone component supplier for the Pentagon's "Drone Dominance" initiative, while its high-profile advisory board member also sparks community discussion around potential future contracts.

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Emergent Biosolutions Inc

Emergent BioSolutions is trending due to recent positive developments, including a significant debt prepayment and an FDA approval for a new Narcan carrying case, though community discussion is heavily focused on a lawsuit against its former CEO which many see as a temporary dip and a strong buying opportunity ahead of anticipated robust earnings and 2026 guidance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Short Interest in Goldman Sachs BDC, Inc. (NYSE:GSBD) Increases By 25.5%

Goldman Sachs BDC, Inc. (NYSE:GSBD - Get Free Report) saw a significant increase in short interest in January. As of January 30th, there was short interest totaling 2,633,872 shares, an increase of...

Goldman Sachs BDC, Inc. (NYSE:GSBD) Given Consensus Rating of "Reduce" by Analysts

Goldman Sachs BDC, Inc. (NYSE:GSBD - Get Free Report) has earned a consensus recommendation of "Reduce" from the five research firms that are covering the company, Marketbeat Ratings reports. Two...

Gladstone Investment (GAIN) Lags Q3 Earnings and Revenue Estimates

Gladstone Investment (GAIN) delivered earnings and revenue surprises of -10.64% and -1.91%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Goldman Sachs BDC, Inc. Schedules Earnings Release and Conference Call to Announce Fourth Quarter and Fiscal Year Ended 2025 Results

Goldman Sachs BDC, Inc. (GS BDC) (NYSE: GSBD) announced today that it will report its fourth quarter and fiscal year ended December 31, 2025 financial results after the market closes on Thursday...

Goldman Sachs BDC, Inc. Prices Public Offering of $400 Million of 5.100% Unsecured Notes Due 2029 Company Release - January 21, 2026

Goldman Sachs BDC, Inc. (the Company) (NYSE: GSBD) announced today that it has priced an offering of $400 million aggregate principal amount of 5.100% notes due 2029 (the Notes). The Notes will...

Goldman Sachs BDC, Inc. (NYSE:GSBD) Short Interest Up 26.1% in December

Goldman Sachs BDC, Inc. (NYSE:GSBD - Get Free Report) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 2,133,906...

Goldman Sachs BDC, Inc. $GSBD Shares Purchased by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. increased its stake in Goldman Sachs BDC, Inc. (NYSE:GSBD - Free Report) by 55.7% in the 3rd quarter, according to the company in its most recent filing with the SEC...

Goldman Sachs BDC (NYSE:GSBD) Sets New 1-Year Low - Here's Why

Goldman Sachs BDC (NYSE:GSBD) Sets New 1-Year Low - Here's Why...

Goldman Sachs BDC, Inc. (NYSE:GSBD) Short Interest Update

Goldman Sachs BDC, Inc. (NYSE:GSBD - Get Free Report) saw a significant decline in short interest in December. As of December 15th, there was short interest totaling 1,692,488 shares, a decline of...

Goldman Sachs BDC (NYSE:GSBD) Sets New 1-Year Low - What's Next?

Goldman Sachs BDC (NYSE:GSBD) Sets New 12-Month Low - Here's What Happened...

Goldman Sachs BDC, Inc. invests in middle market companies located in the United States. The fund targets companies operating in the fields software, health technology information technology, commercial services and textiles with an investment size of $25 to $75 million and an EBITDA of $5 to $75 million. It provides financing in the form of senior secured debt, unitranche debt, junior secured, mezzanine debt and equity for acquisitions, refinancing, growth, LBOs, dividend recapitalization and restructuring transactions.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$0.35	--	--	N/A
Q3 '25	$0.36	$0.40	12.20%	BEAT
Q2 '25	$0.39	$0.38	-3.26%	MISSED
Q1 '25	$0.42	$0.42	-0.89%	MISSED
Q4 '24	$0.50	$0.48	-3.04%	MISSED

GSBD
Goldman Sachs BDC Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest GSBD News

GSBDGoldman Sachs BDC Inc